Collectively, these in vitro and in vivo results strongly support that METTL3 may act as an oncogene and promote tumorigenesis in both cSCC and HNSCC and highlight the potential of targeting aberrant RNA methylation for cancer therapy. This evidence concerns the gene METTL3 and head and neck squamous cell carcinoma.